IDT will be participating in Association for Molecular Pathology (AMP) Annual Meeting 2020 virtually this year. Learn about our solutions for life sciences and medical research, serving the academic, clinical, biotechnology, pharmaceutical development, and agricultural research communities. The conference runs Nov. 16 through Nov. 20.
A Multi-Institutional Collaborative Effort to Facilitate Development and Standardization of Clinical Research Next Generation Sequencing
Jeremy P. Segal, MD, PhD
Director, Genomic and Molecular Pathology
Associate Professor of Pathology
University of Chicago
Co-Founder, Genomic Oncology Academic Laboratory Consortium
Dara L. Aisner
Director, Colorado Molecular Correlates Laboratory
University of Colorado Department of Pathology
The accelerating uptake of NGS in the oncology diagnostics research space has placed a great degree of stress on individual academic laboratories to continually offer the latest in biomarker testing. Inter-institutional collaborative development efforts represent a promising way forward to lessen development burdens and costs and to help promote cross-laboratory concordance. This session introduces the Genomic Oncology Academic Laboratory (GOAL), a consortium designed to facilitate collaboration in this area. GOAL partners with Integrated DNA Technologies, Inc., (IDT) to produce shareable, modular, low-cost hybrid capture systems capable of supporting cooperative, inter-institutional, clinical research, NGS development.
IDT technology update: SARS-CoV-2 research
Brian Krueger, PhD
Associate Vice President
Technical Director, Research and Development
Laboratory Corporation of America
Since January, IDT has offered oligos and probes for the detection of SARS-CoV-2 using third party qPCR protocols, in both stocked and custom formats. We also offer custom guide RNAs for CRISPR-Cas13 research, and our NGS line-up is a great way to start exploring evolutionary questions related to the COVID-19 pandemic. This workshop will discuss traditional and emerging workflows in COVID-19 research, and where our qPCR, CRISPR, and NGS products fit in.